NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

sentiment stocks, good point, the 5 yr data may also help demonstrate benefit for rGBM, which would more certainly show benefit if resections were done upon progression. When you consider the volume of rGBM procedures needed, though DCVax-L will reduce the quantity somewhat, the value of DCVax-L as THE potential GBM treatment is increased considerably. And, actual 5 yr data is the gold standard of data, which is quite rare to have, particularly prior to a BLA submission. Actual 5 yr survival data provides deep efficacy data and actual 5 yr trial data provides deep safety data.